▮Table 2▮.

Comparison of GS-1 and GS-2 in Cases Demonstrating TCR-Vβ Restriction^*

Diagnosis/Case No.	TCR−Vβ Family	GS−1: Vβ−Restricted Gated Cells (%)	GS−2: Vβ−Restricted Gated Cells (%)	Clonality by TCR PCR
ATLL
3	8	30.16	60.49	+
6	9	54.54	58.32	+
7	22	86.45	89.13	+
8	17	18.4	77.46	+
10	1	28.49	84.53	+
11	1	9.2	67.86	+
12	1	54.42	82.84	+
14	22	69.09	81.83	+
15	18	86.04	92.06	+
16	17	95.45	98.23	+
17	5.1	98.02	†	+
19	17	53.6	70.75	+
21	5.1	87.91	98.37	+
22	9	6.72	63.05	+
24	13.1	80.19	83.56	ND
CTCL
26	21.3	91.71	97.91	+
28	8	92.02	98.60	+
29	14	99.31	†	ND
30	13.2	87.0	92.70	+
31	20	97.78	†	ND
PTCL
32	4	53.06	86.67	+
33	17	80.94	98.68	+
34	17	91.27	95.15	+
TPLL
35	13.1	93.79	98.00	+
LGL
36	3	63.58	‡	+
39	7.1	98.45	†	+
40	8	97.49	†	+

ATLL, human T-lymphotropic virus-1–associated adult T-cell leukemia/lymphoma; CTCL, cutaneous T-cell lymphoma; GS-1, gating strategy 1; GS-2, gating strategy 2; LGL, T-cell large granular lymphocytic leukemia; ND, not done; PCR, polymerase chain reaction; PTCL, peripheral T-cell lymphoma, not otherwise specified; TCR, T-cell receptor; TPLL, T-cell prolymphocytic leukemia; +, TCR clonal rearrangement detected.

^*Mean (range) for GS-1, 70.6% (6.72%−99.31%); and for GS-2, 84.6% (58.32%−98.68%).

^†All CD4+ or CD8+ T cells are neoplastic, and GS-2 is not applicable.

^‡No apparent aberrancy in T-cell antigen expression detected, and GS-2 is not applicable.